文献速递临床试验与 GCP

比例辅助通气以缩短机械通气时长

Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation.
PubMed 文献 · N Engl J Med · 2025-06-13

这项国际临床试验将573例已接受机械通气至少24小时、能耐受部分通气支持但尚未准备脱机的成人患者随机分配至PAV+或PSV组,主要结局为随机至成功脱机的时间。PAV+组中位脱机时间7.3天(95%CI 6.2~9.7),PSV组6.8天(95%CI 5.4~8.8),差异无统计学意义(P=0.58);无呼吸机天数、再插管、气管切开及90天死亡率等次要结局两组相似。

要点

  • PAV+与PSV相比,成功脱机时间无显著差异(P=0.58)。
  • 90天死亡率PAV+组29.6% vs PSV组26.6%,两组相似。
  • 严重不良事件PAV+组31例(10.8%) vs PSV组28例(9.8%),P=0.79。

核心结论

  • PAV+组与PSV组从随机至成功脱机的时间无显著差异。

研究设计与样本

  • 国际临床试验,在7个国家23个中心纳入722例患者,其中573例随机分组并纳入分析。
  • 纳入标准为成人患者已接受机械通气至少24小时、能耐受PSV部分通气支持但尚未准备脱机。
  • 随机分配至PAV+(目标为正常呼吸功)或PSV(目标为正常呼吸频率和潮气量)。

主要发现

  • PAV+组中位成功脱机时间7.3天(95%CI 6.2~9.7),PSV组6.8天(95%CI 5.4~8.8),P=0.58。
  • PAV+组90天死亡率29.6%,PSV组26.6%,两组相似。
  • 第28天与基线相比咪达唑仑等效剂量平均(±SD)差值:PAV+组-1.51±3.28 mg/kg,PSV组0.04±0.97 mg/kg。
  • 严重不良事件PAV+组31例(10.8%),PSV组28例(9.8%),P=0.79。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In critically ill patients, acceleration of liberation from mechanical ventilation is important in order to reduce the risk of complications and to improve long-term outcomes. Whether the use of proportional-assist ventilation with load-adjustable gain factors (PAV+) results in a shorter time to successful liberation from mechanical ventilation than pressure-support ventilation (PSV) is unclear. METHODS: In this international clinical trial, we randomly assigned adult patients who had been receiving mechanical ventilation for at least 24 hours and were able to undergo partial ventilatory support with PSV but were not yet ready for liberation from ventilation to undergo PAV+ (which targeted normal work of breathing) or PSV (which targeted a normal respiratory rate and tidal volume). The primary outcome was the time from randomization to successful liberation from mechanical ventilation. RESULTS: Across 23 centers in seven countries, 722 patients were enrolled, and 573 underwent randomization and were included in the analysis. The median time to successful liberation from mechanical ventilation was 7.3 days (95% confidence interval [CI], 6.2 to 9.7) in the PAV+ group and 6.8 days (95% CI, 5.4 to 8.8) in the PSV group (P = 0.58). The median number of ventilator-free days, the incidence of reintubation and tracheostomy, and the incidence of death by day 90 (29.6% in the PAV+ group and 26.6% in the PSV group), all of which were secondary outcomes, were similar in the two groups. With respect to sedative drugs, the mean (±SD) difference in the midazolam-equivalent dose at day 28 relative to the baseline dose was -1.51±3.28 mg per kilogram of body weight in the PAV+ group and 0.04±0.97 mg per kilogram in the PSV group. Serious adverse events occurred in 31 patients (10.8%) in the PAV+ group and in 28 patients (9.8%) in the PSV group (P = 0.79). CONCLUSIONS: The time to liberation from mechanical ventilation did not differ significantly between the group that underwent PAV+ and the group that underwent PSV. (Funded by the Canadian Institutes of Health Research and others; PROMIZING ClinicalTrials.gov number, NCT02447692.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Bosma KJ, Burns KEA, Martin CM, et al. Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation. N Engl J Med. 2025. PMID: 40513024. doi:10.1056/NEJMoa2505708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。